查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2117036

基於分子開關的標靶治療市場：按應用、治療標靶、最終用戶、國家及地區分類－全球產業分析、市場規模、市場佔有率及2026年至2033年預測

Molecular Switch Targeting Therapies Market, By Application Area, By Target Therapy, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 249 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，使用分子開關的標靶治療市場規模將達到 8.304 億美元，並預計從 2026 年到 2033 年將以 13.5% 的複合年成長率成長。

基於分子開關的標靶治療是一種創新藥物，它利用基因改造的開關來控制藥物給藥後細胞內的治療功能、持續時間、結合和安全性。分子開關市場涵蓋可切換的CAR-T細胞構建體、藥物結合受體、適配器、誘導型安全開關和基因治療平台。這項技術可應用於多種疾病的治療，包括腫瘤、自體免疫疾病和發炎性疾病、神經科學以及某些再生醫學領域。

多家公司正致力於開發類似的化學開關，以微調治療效果。然而，分子開關技術的主要挑戰在於如何穩定地生產這些開關以及如何在臨床上驗證其療效。 2025年，Calibr公司的候選治療藥物CLBR001和開關平台SWI019進入臨床試驗階段。這表明分子開關本身正在成為治療手段。因此，可控性不再是次要因素，而是創新細胞和基因療法的關鍵組成部分。

利用分子開關的標靶治療市場—市場動態

可程式設計治療控制正在拓展生物製藥的效用。

隨著研發人員對生物製藥的控制需求日益成長，給藥後調節治療活性的能力變得愈發重要。現有的CAR-T療法在移植後能夠維持細胞活性和治療效果，但當持續的免疫反應並非理想狀態時，就會面臨挑戰。分子開關透過將開關活化與給藥分子關聯起來，實現了更精細的控制，使臨床醫生能夠更精確地調整治療劑量，避免治療細胞被完全清除。這種機制尤其適用於自體免疫疾病的風險獲益比更為複雜，治療週期也比癌症治療更長。 Calibr公司於2025年啟動了一項針對四種自體免疫疾病的I期臨床試驗計畫。這不僅拓展了CAR-T技術在癌症領域的應用，也凸顯了可程式設計控制技術的價值，並展現了其進一步拓寬CAR-T療法應用範圍、使其惠及所有疾病領域的潛力。

分子開關標標靶治療市場—區域洞察

北美憑藉其專業的臨床中心、細胞工程技術、載體生產基礎設施以及在細胞和基因治療領域的監管經驗，在分子開關標靶治療中保持著強大的地位。同時，美國也為基因修飾免疫療法的快速開發和商業化提供了機會。 2025年，FDA批准了Breyanzi用於治療周邊區域淋巴瘤，擴大了CAR-T細胞療法可治療的淋巴瘤範圍。因此，目前的臨床格局為下一代可切換療法的開發和差異化奠定了基礎。由此可見，北美是引入可程式設計控制方法於細胞療法的關鍵地區。

歐洲擁有完善的法律規範、先進的研究基礎設施以及強大的轉化環境，有利於分子開關療法的開發。歐洲藥品管理局（EMA）的先進療法委員會負責評估複雜的細胞和基因療法，確保研發者能夠提供關於品質、生產流程、生物機制和臨床適應症的充分證據。 2025年，EMA的優先藥物（PRIME）計畫遴選了16種藥物，該計畫旨在為滿足高度未滿足的醫療需求的藥物研發者提供科學和監管支援。雖然PRIME計畫並非分子開關療法的專屬，但它凸顯了歐洲致力於推動創新方法治療複雜疾病的決心。因此，歐洲為基於細胞的可程式療法提供了完善的法規環境，並擁有先進的科學技術。

目錄

第1章：分子開關標標靶治療市場概述

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：利用分子開關的標靶治療的關鍵市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：利用分子開關進行標靶治療的產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章 利用分子開關的標靶治療市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：利用分子開關的標靶治療的市場趨勢

  • 2025年基於分子開關的標靶治療市場佔有率分析
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章 基於分子標靶治療市場：依應用領域分類

  • 概述
    • 基於細分市場的市佔率分析：按應用領域分類
    • 自體免疫疾病與發炎性疾病
    • 腫瘤學
    • 神經病變
    • 其他

第8章標靶治療市場：基於分子開關的標靶治療方法

  • 概述
    • 細分市場佔有率分析：按標靶治療
    • CAR-T細胞療法
    • 基因治療
    • 其他細胞和基因療法

第9章 基於分子標靶治療市場：依最終用戶分類

  • 概述
    • 基於細分市場的市場佔有率分析：按最終用戶分類
    • 生技公司
    • 製藥公司
    • 學術研究機構
    • 受託研究機構（CRO）
    • 其他

第10章 基於分子標靶治療市場：按地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第11章：主要供應商分析：利用分子開關的標靶治療產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • aceRNA Technologies
    • Autolus Therapeutics plc
    • Bellicum Pharmaceuticals, Inc.
    • Cellectis SA
    • Kiromic BioPharma, Inc.
    • panCELLa Inc.
    • Precigen, Inc.
    • Sana Biotechnology, Inc.
    • Sangamo Therapeutics, Inc.
    • Editas Medicine, Inc.
    • Merck & Co., Inc.
    • Bristol Myers Squibb
    • AbbVie Inc.
    • Sanofi
    • Regeneron Pharmaceuticals, Inc.
    • Others

第12章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7309

Molecular Switch Targeting Therapies Market size was valued at US$ 830.4 Million in 2025, expanding at a CAGR of 13.5% from 2026 to 2033.

Molecular switch targeting therapies are innovative medicinal products that utilize engineered switches to control therapeutic function, persistence, engagement, and safety profiles in cells after drug administration. The molecular switch market consists of switchable CAR-T constructs, drug-coupled receptors, adapters, inducible safety switches, and gene-therapy platforms. It targets a wide range of diseases, including oncology, autoimmune and inflammatory disorders, neuroscience, and certain regenerative medicine conditions.

Companies work on similar chemical switches that allow for fine-tuning of therapy potency. At the same time, the key challenges for molecular switch technologies are the consistent production of these switches and the clinical validation of their performance. In 2025, Calibr's therapeutic candidate CLBR001 and switch platform SWI019 entered the clinic, indicating that molecular switches are becoming therapeutics themselves. Thus, controllability is no longer an afterthought but rather a critical component of innovative cell and gene medicines.

Molecular Switch Targeting Therapies Market- Market Dynamics

Programmable Therapeutic Control Is Expanding the Utility of Living Medicines

The ability to regulate therapeutic activity after administration is becoming increasingly important as developers seek greater control over living medicines. Existing CAR-T therapies can remain viable and therapeutically active post-transplant, which poses a problem when continued immune engagement is unwanted. Molecular switches give added control by linking activation of a switch to an administered molecule, potentially enabling clinicians to titrate therapy and avoid complete elimination of therapeutic cells. This mechanism is ideally suited to autoimmune diseases-a context wherein treatment entails more risk-benefit and longer treatment cycles than oncology Target Therapys. Calibr developed a Phase 1 program across four autoimmune indications starting in 2025, expanding on the technology into this non-oncologic field and highlighting the value proposition for programmable control to extend CAR-T Target Therapys further up the chain into an entire spectrum of diseases.

Molecular Switch Targeting Therapies Market- Geographical Insights

North America maintains a strong position in molecular-switch targeting therapies due to the presence of specialized clinical centers, cell engineering expertise, vector manufacturing infrastructure, and regulatory experience with cellular and gene therapies. At the same time, the U.S. offers opportunities for rapid development and commercialization of engineered immune-cell therapeutics. In 2025, the FDA approved Breyanzi for the treatment of marginal zone lymphoma, thereby expanding the range of lymphomas for CAR-T cell therapy. Thus, the current clinical landscape creates the basis for the development and differentiation of the next-generation switchable therapeutics. As a result, North America has become an important region for implementing programmable control approaches to cellular therapeutics.

Europe is characterized by a comprehensive regulatory framework, advanced research infrastructure, and a strong translational environment for developing molecular-switch therapeutics. The EMA's Advanced Therapies Committee evaluates complex cell and gene therapies, ensuring that developers generate relevant evidence on quality, manufacturing processes, biological mechanisms, and clinical indications. In 2025, 16 medicines were selected for the EMA's PRIME (Priority Medicines) scheme, which provides scientific and regulatory support to developers of medicines with high unmet clinical needs. Although the PRIME designation does not specifically focus on molecular-switch therapies, this scheme highlights the region's commitment to promoting innovative approaches to treating complex diseases. As a result, for cell-based programmable therapeutics, Europe offers a comprehensive regulatory environment combined with high-level scientific expertise.

Molecular Switch Targeting Therapies Market- Competitive Landscape:

The competition to develop cellular therapies has shifted towards the degree of control over treatment by engineers and is no longer focused on the intricacies of CAR design. Thus, firms are investing heavily in engineering cells where control over activation is achieved through adapted T-cell engagement, receivable signaling to drug-like molecules, inducible safety switches, persistence regulation, vector construction, and manufacturing processes that facilitate the preservation of critical quality attributes. Cell therapy developers with substantial clinical and regulatory expertise have advantages over those that only specialize in biotech, but the latter can profit from investing in switch technologies and partnerships. In 2025, Breyanzi extended the list of approved cancers in the US to five, indicating the value of cellular therapy producers that utilize validated CAR-T platforms. Moreover, it can be expected that cellular therapy producers will gain advantages by combining robustness in therapeutic cell types with external control mechanisms and individual adjustments.

Recent Developments:

In April 2025, Calibr announced the initiation of a Phase I clinical trial evaluating the combination of the switchable CAR-T platform CLBR001 and SWI019 to treat four autoimmune diseases.

In December 2025, Bristol Myers Squibb's Breyanzi was approved by the FDA for the treatment of patients with relapsed or refractory marginal zone lymphoma.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • aceRNA Technologies
  • Autolus Therapeutics plc
  • Bellicum Pharmaceuticals, Inc.
  • Cellectis S.A.
  • Kiromic BioPharma, Inc.
  • panCELLa Inc.
  • Precigen, Inc.
  • Sana Biotechnology, Inc.
  • Sangamo Therapeutics, Inc.
  • Editas Medicine, Inc.
  • Merck & Co., Inc.
  • Bristol Myers Squibb
  • AbbVie Inc.
  • Sanofi
  • Regeneron Pharmaceuticals, Inc.
  • Others

GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET, BY APPLICATION AREA- MARKET ANALYSIS, 2020 - 2033

  • Management of Treatment-Related Toxicity
  • Regulation of Gene Expression
  • Others

GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET, BY TARGET THERAPY- MARKET ANALYSIS, 2020 - 2033

  • CAR-T Cell Therapy
  • Gene Therapy
  • Other Cell & Gene Therapies

GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

  • Biotechnology Companies
  • Pharmaceutical Companies
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)
  • Others

GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Molecular Switch Targeting Therapies Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
  • 2.2. Competitive Insights

3. Molecular Switch Targeting Therapies Key Market Trends

  • 3.1. Molecular Switch Targeting Therapies Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Molecular Switch Targeting Therapies Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Molecular Switch Targeting Therapies Market Opportunities
  • 3.4. Molecular Switch Targeting Therapies Market Future Trends

4. Molecular Switch Targeting Therapies Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Molecular Switch Targeting Therapies Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Molecular Switch Targeting Therapies Market Landscape

  • 6.1. Molecular Switch Targeting Therapies Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Molecular Switch Targeting Therapies Market - By Application Area

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Application Area, 2025 & 2033 (%)
    • 7.1.2. Autoimmune and Inflammatory Disorders
    • 7.1.3. Oncology
    • 7.1.4. Neurological Disorders
    • 7.1.5. Others

8. Molecular Switch Targeting Therapies Market - By Target Therapy

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Target Therapy, 2025 & 2033 (%)
    • 8.1.2. CAR-T Cell Therapy
    • 8.1.3. Gene Therapy
    • 8.1.4. Other Cell & Gene Therapies

9. Molecular Switch Targeting Therapies Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
    • 9.1.2. Biotechnology Companies
    • 9.1.3. Pharmaceutical Companies
    • 9.1.4. Academic & Research Institutes
    • 9.1.5. Contract Research Organizations (CROs)
    • 9.1.6. Others

10. Molecular Switch Targeting Therapies Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Molecular Switch Targeting Therapies Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Molecular Switch Targeting Therapies Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.16. Denmark
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.16.3. Denmark Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.3.16.4. Denmark Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.3.16.5. Denmark Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.17. Rest of Europe
      • 10.3.17.1. Overview
      • 10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.17.3. Rest of the Europe Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.3.17.4. Rest of the Europe Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.3.17.5. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Molecular Switch Targeting Therapies Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.15. Taiwan
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.15.3. Taiwan Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.4.15.4. Taiwan Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.4.15.5. Taiwan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.16. Vietnam
      • 10.4.16.1. Overview
      • 10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.16.3. Vietnam Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.4.16.4. Vietnam Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.4.16.5. Vietnam Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.17. Rest of APAC
      • 10.4.17.1. Overview
      • 10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.17.3. Rest of APAC Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.4.17.4. Rest of APAC Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.4.17.5. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Molecular Switch Targeting Therapies Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Molecular Switch Targeting Therapies Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.13. Iran
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.13.3. Iran Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.6.13.4. Iran Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.6.13.5. Iran Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.14. Qatar
      • 10.6.14.1. Overview
      • 10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.14.3. Qatar Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.6.14.4. Qatar Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.6.14.5. Qatar Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.15. Rest of MEA
      • 10.6.15.1. Overview
      • 10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.15.3. Rest of MEA Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
      • 10.6.15.4. Rest of MEA Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
      • 10.6.15.5. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

11. Key Vendor Analysis- Molecular Switch Targeting Therapies Industry

  • 11.1. Competitive Benchmarking
    • 11.1.1. Competitive Dashboard
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. aceRNA Technologies
    • 11.2.2. Autolus Therapeutics plc
    • 11.2.3. Bellicum Pharmaceuticals, Inc.
    • 11.2.4. Cellectis S.A.
    • 11.2.5. Kiromic BioPharma, Inc.
    • 11.2.6. panCELLa Inc.
    • 11.2.7. Precigen, Inc.
    • 11.2.8. Sana Biotechnology, Inc.
    • 11.2.9. Sangamo Therapeutics, Inc.
    • 11.2.10. Editas Medicine, Inc.
    • 11.2.11. Merck & Co., Inc.
    • 11.2.12. Bristol Myers Squibb
    • 11.2.13. AbbVie Inc.
    • 11.2.14. Sanofi
    • 11.2.15. Regeneron Pharmaceuticals, Inc.
    • 11.2.16. Others

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us